Precirix, a leader in the development of precision radiopharmaceuticals using camelid single-domain antibodies as targeting vectors, is proud to launch an academic access program for their proprietary molecule CAM-FAP-Ga-68. The primary aim of the program is to broaden the availability of innovative radiopharmaceuticals that are still under investigation to physicians and researchers. By providing access to CAM-FAP-Ga-68, the program supports research, enhances clinical knowledge, and fosters collaborations that may lead to new applications or improvements in patient care.
Go to Precirix.com/FAP-access for more information and to get in contact with a CAM-FAP Academic Access Program team member.
Your browser is not supported. Update your browser for more security, speed and to make the most of this site.